You searched for "Tumour"

222 results found

The evaluation of CT urography in the haematuria clinic

This retrospective study examined the records of 1000 patients attending a haematuria clinic over a two-year period. All patients over 40 with visible (VH) or non-visible haematuria (NVH) had a computed tomography urogram (CTU) and a flexible cystoscopy (if not...

Non-urothelial tumours of bladder – impact on oncological outcomes

Non-urothelial bladder tumours are not very common and they are generally considered to be high risk tumours when compared to standard urothelial tumours. In this study the researchers analysed the oncological outcomes of patients with such histology in comparison to...

Immunotherapy in renal cancer

Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...

Modern management of small renal masses

With the advent of widespread cross-sectional imaging there has been a surge in incidental detection of small renal masses (SRMs) and renal cell carcinoma (RCC) is now the seventh most common cancer in the UK. Whilst surgical excision for larger...

Small renal masses – diagnosis and management

Renal cancer is the eighth most common cancer in the UK and accounts for about 3% of all new cancer diagnoses [1]. The incidence rates are steadily rising, with the highest rates being in older men and women. This rise...

Repeat transurethral resection in non-muscle invasive bladder cancer

The authors felt this is a big problem because there is no standardised practice on re-resection following initial transurethral resection of bladder tumour (TURBT). Getting detrusor muscle in the first specimen is thought to be important. However muscle is not...

Active surveillance for small renal masses in younger patients

Active surveillance (AS) is discussed as an option for renal masses <2cm in patients with significant competing risks for mortality. This multicentre data from the US seeks to fill an important gap in current guidelines for provision of this option...

Thulium laser: the new kid ‘en bloc’

Transurethral resection of bladder tumour (TURBT) is considered the gold standard for management of bladder cancer. Residual rates of 15-53% at second TURB and upstaging rates of 4-29% with muscle invasion have been reported. The quality and result of the...

Phase two trial of SAbR for primary RCC

A study focused on stereotactic ablative radiotherapy (SAbR) as a treatment for primary renal cell carcinoma (RCC) has yielded significant findings. The primary objective of the study was successfully met, demonstrating a 94% local control rate at one year among...

Comparative effectiveness of nephron sparing surgery vs ablation

Nephron sparing surgery (NSS) and minimally invasive modality of thermal ablation have attracted great attention as an alternative surgical treatment to radical nephrectomy (RN) for renal tumours <4cm. High quality evidence comparing disease specific survival (DSS) is lacking. This issue...

Management of stage 1 non-seminomatous germ cell tumours

Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Sarcomatoid renal cell carcinoma

Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...